References
- Allen CE, Li L, Peters TL, Leung H-CE, Yu A, Man T-K, et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol. 2010; 184:4557–67.
- Badalian-Very G, Vergilio J-A, Degar BA, Rodriguez-Galindo C, Rollins BJ. Recent advances in the understanding of Langerhans cell histiocytosis. Br J Haematol. 2012; 156:163–72.
- Héritier S, Emile J-F, Barkaoui M-A, Thomas C, Fraitag S, Boudjemaa S, et al. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol. 2016; 34:3023–30.
- Kobayashi M, Tojo A. Langerhans cell histiocytosis in adults: advances in pathophysiology and treatment. Cancer Sci. 2018; 109:3707–13.
- Bhatia P, Singh M, Sharma M, Sharma A, Kakkar N, Radhika S, et al. BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival. Blood Cells Mol Dis. 2020; 82:102356. doi: 10.1016/j.bcmd.2019.102356
- Ribeiro KB, Degar B, Antoneli CB, Rollins B, Rodriguez-Galindo C. Ethnicity, race, and socioeconomic status influence incidence of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2015; 62:982–7.
- Salotti JA, Nanduri V, Pearce MS, Parker L, Lynn R, Windebank KP. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child. 2009; 94:376–80.
- Bidwell SS, Peterson CC, Demanelis K, Zarins KR, Meza R, Sriplung H, et al. Childhood cancer incidence and survival in Thailand: A comprehensive population-based registry analysis, 1990–2011. Pediatr Blood Cancer. 2019; 66:e27428. doi: 10.1002/pbc.27428
- Wiangnon S, Kamsa-Ard S, Jetsrisuparb A, Sriplung H, Sontipong S, Sumitsawan Y, Martin N. Childhood cancer in Thailand: 1995–1997. Asian Pac J Cancer Prev. 2003; 4:337–43.
- Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020; 135:1319–31.
- Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med. 2018; 379:856–68.
- Monsereenusorn C, Rodriguez-Galindo C. Clinical characteristics and treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 2015; 29:853–73.
- Haupt R, Minkov M, Astigarraga I, Schääfer E, Nanduri V, Jubran R, et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013; 60:175–84.
- Jessop S, Crudgington D, London K, Kellie S, Howman-Giles R. FDG PET-CT in pediatric Langerhans cell histiocytosis. Pediatr Blood Cancer. 2020; 67:e28034. doi: 10.1002/pbc.28034
- Monsereenusorn C, Minkov M, Rodriguez-Galindo C. Current treatment of Langerhans cell histiocytosis. Expert Opin Orphan Drugs. 2016; 4:1057–68.
- Krooks J, Minkov M, Weatherall AG. Langerhans cell histiocytosis in children: diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up. J Am Acad Dermatol. 2018; 78:1047–56.
- Gadner H, Grois N, Potschger U, Minkov M, Arico M, Braier J, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008; 111:2556–62.
- Gadner H, Minkov M, Grois N, Pötschger U, Thiem E, Arico M, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013; 121:5006–14.
- Imashuku S, Kinugawa N, Matsuzaki A, Kitoh T, Ohki K, Shioda Y, et al.; Japan LCH Study Group. Langerhans cell histiocytosis with multifocal bone lesions: comparative clinical features between single and multi-systems. Int J Hematol. 2009; 90:506–12.
- Gao Y-J, Su M, Tang J-Y, Pan C, Chen J. Treatment outcome of children with multisystem Langerhans cell histiocytosis: the experience of a single children's hospital in Shanghai, China. J Pediatr Hematol Oncol. 2018; 40:e9–12. doi: 10.1097/MPH.0000000000001016
- Su M, Gao YJ, Pan C, Chen J, Tang JY. Outcome of children with Langerhans cell histiocytosis and single-system involvement: a retrospective study at a single center in Shanghai, China. Pediatr Hematol Oncol. 2018; 35:385–92.
- Morimoto A, Shioda Y, Imamura T, Kudo K, Kitoh T, Kawaguchi H, et al.; Japan LCH Study Group. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol. 2018; 108:192–8.
- Morimoto A, Shioda Y, Imamura T, Kudo K, Kawaguchi H, Sakashita K, et al. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol. 2016; 104:99–109.
- North American Consortium for Histiocytosis. LCH-IV, International collaborative treatment protocol for children and adolescents with Langerhans cell histiocytosis [Internet]. ClinicalTrials.gov. 2021 [cited 2021 May 9]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02205762
- Minkov M, Grois N, Heitger A, Pötschger U, Westermeier T, Gadner H. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr. 2000; 212:139–44.
- Gadner H, Heitger A, Grois N, Gatterer-Menz I, Ladisch S. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol. 1994; 23:72–80.
- Wang D-S, Lu M-Y, Yang Y-L, Lin D-T, Lin K-H, Chang H-H, Jou S-T. Clinical outcomes of childhood Langerhans cell histiocytosis in Taiwan: a single-center, 20-year experience. J Formos Med Assoc. 2021; 120:594–601.
- Stålemark H, Laurencikas E, Karis J, Gavhed D, Fadeel B, Henter J-I. Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr Blood Cancer. 2008; 51:76–81.
- Donadieu J, Rolon M-A, Thomas C, Brugieres L, Plantaz D, Emile JF, et al. Endocrine involvement in pediatric-onset Langerhans’ cell histiocytosis: a population-based study. J Pediatr. 2004; 144:344–50.
- Poompuen S, Chaiyarit J, Techasatian L. Diverse cutaneous manifestation of Langerhans cell histiocytosis: a 10-year retrospective cohort study. Eur J Pediatr. 2019; 178:771–6.
- Zhang X, Zhou J, Chai X, Chen G, Guo B, Ni L, et al. The application of x-ray, computed tomography, and magnetic resonance imaging on 22 pediatric Langerhans cell histiocytosis patients with long bone involvement: a retrospective analysis. Medicine (Baltimore). 2018; 97:e0411. doi: 10.1097/MD.0000000000010411
- Meyer JS, Harty MP, Mahboubi S, Heyman S, Zimmerman RA, Womer RB, et al. Langerhans cell histiocytosis: presentation and evolution of radiologic findings with clinical correlation. Radiographics. 1995; 15:1135–46.
- Kim JR, Yoon HM, Jung AY, Cho YA, Seo JJ, Lee JS. Comparison of whole-body MRI, bone scan, and radiographic skeletal survey for lesion detection and risk stratification of Langerhans cell histiocytosis. Sci Rep. 2019; 9:317. doi: 10.1038/s41598-018-36501-1
- Phillips M, Allen C, Gerson P, McClain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009; 52:97–101.
- Guo Y, Ning F, Wang G, Li X, Liu J, Yuan Y, Dai P. Retrospective study of Langerhans cell histiocytosis in ear, nose and neck. Am J Otolaryngol. 2020; 41:102369. doi: 10.1016/j.amjoto.2019.102369
- Morimoto A, Ikushima S, Kinugawa N, Ishii E, Kohdera U, Sako M, et al.; Japan Langerhans Cell Histiocytosis Study Group. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer. 2006; 107:613–9.
- Braier JL, Rosso D, Latella A, Chantada G, Ozuna B, Ripoli M, Scopinaro M. Importance of multi-lineage hematologic involvement and hypoalbuminemia at diagnosis in patients with “risk-organ” multi-system Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2010; 32:e122–5. doi: 10.1097/MPH.0b013e3181d7acc5
- Totadri S, Bansal D, Trehan A, Srinivasan R, Varma N, Kakkar N, et al. The 5-year EFS of multisystem LCH with risk-organ involvement is suboptimal: a single-center experience from India. J Pediatr Hematol Oncol. 2016; 38:e1–5. doi: 10.1097/MPH.0000000000000414
- Bernard F, Thomas C, Bertrand Y, Munzer M, Landman Parker J, Ouache M, et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer. 2005; 41:2682–9.
- Gandolfi L, Adamo S, Pileri A, Broccoli A, Argnani L, Zinzani PL. Multisystemic and multiresistant Langerhans cell histiocytosis: a case treated with BRAF inhibitor. J Natl Compr Canc Netw. 2015; 13:715–8.
- Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013; 121:1495–500.